Patents by Inventor Stefan Haertle

Stefan Haertle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD38 ANTIBODIES FOR USE IN THE TREATMENT OF ANTIBODY-MEDIATED TRANSPLANT REJECTION
    Publication number: 20240132618
    Abstract: The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.
    Type: Application
    Filed: March 1, 2022
    Publication date: April 25, 2024
    Inventors: Stefan Steidl, Stefan Härtle, Rainer Boxhammer
  • ANTI-CD38 ANTIBODIES AND THEIR USES
    Publication number: 20240109977
    Abstract: The present invention relates to the use of an anti-CD38 antibody or antibody fragment in the prophylaxis and/or treatment of diseases directly caused by immune complex deposits. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of IgA nephropathy (IgAN).
    Type: Application
    Filed: January 14, 2022
    Publication date: April 4, 2024
    Inventors: Stefan Steidl, Stefan Härtle, Rainer Boxhammer
  • COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USE
    Publication number: 20240067753
    Abstract: The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.
    Type: Application
    Filed: March 30, 2023
    Publication date: February 29, 2024
    Inventors: Stefan HAERTLE, Christian FRISCH, Achim KNAPPIK
  • Treatment Paradigm for an Anti-CD19 Antibody Therapy
    Publication number: 20230357392
    Abstract: The present disclosure provides anti-CD19 antibodies for use in the treatment of various cancers. The anti-CD19 antibody is administered to cancer patients in a specific dose or dosing regimen.
    Type: Application
    Filed: December 22, 2022
    Publication date: November 9, 2023
    Inventors: Stefan HÄRTLE, Frank STRIEBEL
  • CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA
    Publication number: 20230203189
    Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the antibody in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
    Type: Application
    Filed: February 14, 2023
    Publication date: June 29, 2023
    Inventor: Stefan Härtle
  • TREATMENT OF ATOPIC DERMATITIS
    Publication number: 20230203149
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody for antibody fragment specific for IL-17C, in particular MOR106 for use in the treatment of atopic dermatitis and related conditions wherein the antibody is administered to patients at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: September 25, 2018
    Publication date: June 29, 2023
    Inventors: Stefan Haertle, Tim Van Kaem, Frederic Paul Vanhoutte
  • Clinical assessment of M-protein response in multiple myeloma
    Patent number: 11618789
    Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti-body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 4, 2023
    Assignee: MORPHOSYS AG
    Inventor: Stefan Härtle
  • Treatment for multiple myeloma (MM)
    Patent number: 11591406
    Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: February 28, 2023
    Assignee: MORPHOSYS AG
    Inventors: Stéphane LeClair, Jan Endell, Stefan Härtle
  • ANTI-CD38 ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF AUTOANTIBODY-MEDIATED AUTOIMMUNE DISEASE
    Publication number: 20220144965
    Abstract: The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of anti-PLA2R positive membranous glomerulonephropathy.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Inventors: Daniel KLUNKER, Rainer BOXHAMMER, Stefan HÄRTLE, Stefan STEIDL, Tiantom JARUTAT
  • COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USE
    Publication number: 20200339703
    Abstract: The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.
    Type: Application
    Filed: July 10, 2020
    Publication date: October 29, 2020
    Inventors: Stefan HAERTLE, Christian FRISCH, Achim KNAPPIK
  • Complex-specific antibodies and antibody fragments and its use
    Patent number: 10774154
    Abstract: The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 15, 2020
    Assignee: MORPHOSYS AG
    Inventors: Stefan Haertle, Christian Frisch, Achim Knappik
  • TREATMENT FOR MULTIPLE MYELOMA (MM)
    Publication number: 20200079871
    Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 12, 2020
    Inventors: Stéphane LeClair, Jan Endell, Stefan Härtle
  • Treatment for multiple myeloma (MM)
    Patent number: 10533057
    Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: January 14, 2020
    Assignee: MORPHOSYS AG
    Inventors: Stéphane LeClair, Jan Endell, Stefan Härtle
  • CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA
    Publication number: 20190077875
    Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti-body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
    Type: Application
    Filed: March 3, 2017
    Publication date: March 14, 2019
    Applicant: MORPHOSYS AG
    Inventor: Stefan Härtle
  • TREATMENT FOR MULTIPLE MYELOMA (MM)
    Publication number: 20190048091
    Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
    Type: Application
    Filed: May 13, 2016
    Publication date: February 14, 2019
    Inventors: Stéphane LeClair, Jan Endell, Stefan Härtle
  • COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USE
    Publication number: 20180134807
    Abstract: The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.
    Type: Application
    Filed: December 19, 2017
    Publication date: May 17, 2018
    Inventors: Stefan HAERTLE, Christian FRISCH, Achim KNAPPIK
  • Use of lysozyme as a tag
    Patent number: 9689014
    Abstract: The present disclosure provides a method to express and purify polypeptides and proteins. In the present disclosure the use of lysozyme as a fusion partner is disclosed. Furthermore, purification methods to isolate lysozyme-tagged polypeptides and proteins via lysozyme-specific antibodies are described. More specifically, the present disclosure provides a method to express and purify monomeric polypeptides and proteins by using lysozyme as a tag.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: June 27, 2017
    Assignee: MORPHOSYS AG
    Inventors: Stefan Haertle, Sebastian Jaeger, Daniela Daubert
  • Use of lysozyme as a tag
    Publication number: 20140349343
    Abstract: The present disclosure provides a method to express and purify polypeptides and proteins. In the present disclosure the use of lysozyme as a fusion partner is disclosed. Furthermore, purification methods to isolate lysozyme-tagged polypeptides and proteins via lysozyme-specific antibodies are described. More specifically, the present disclosure provides a method to express and purify monomeric polypeptides and proteins by using lysozyme as a tag.
    Type: Application
    Filed: January 23, 2013
    Publication date: November 27, 2014
    Inventors: Stefan Haertle, Sebastian Jaeger, Daniela Daubert